Whitehawk Therapeutics
WHWK
50 hedge funds and large institutions have $56.4M invested in Whitehawk Therapeutics in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 11 closing their positions.
1,525% more call options, than puts
Call options by funds: $65K | Put options by funds: $4K
68.15% more ownership
Funds ownership: 60.64% → 128.79% (+68%)
19% more capital invested
Capital invested by funds: $47.2M → $56.4M (+$9.15M)
6% less funds holding
Funds holding: 53 → 50 (-3)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$10.9M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$9.66M |
| 3 |
QF
QVT Financial
New York
|
+$5.75M |
| 4 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$5.44M |
| 5 |
YF
Yu Fan
|
+$5.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.05M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$548K |
| 3 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$526K |
| 4 |
Millennium Management
New York
|
-$337K |
| 5 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$201K |
WHWK Hedge Fund Activity: Q1 2025 in Review
50 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q1 2025, worth a combined $56.4M — up 19% from $47.2M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of WHWK and 9 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 13 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $10.9M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $1.05M sold.
- 50 institutional investors held Whitehawk Therapeutics (WHWK) as of Q1 2025, down from 53 in Q4 2024.
- Funds reported $56.4M of Whitehawk Therapeutics stock for Q1 2025, up 19% quarter-over-quarter.
- 9 funds opened new Whitehawk Therapeutics positions in Q1 2025 and 11 closed out, a net change of -2 holders.
- The largest Whitehawk Therapeutics buyer in Q1 2025 was OrbiMed, an estimated $10.9M added.
- The largest Whitehawk Therapeutics seller in Q1 2025 was Soleus Capital Management, an estimated $1.05M sold.
Based on aggregated 13F filings for Q1 2025.